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Background:The procognitive actions of the nicotinic acetylcholine receptor (nAChR) ago-
nist nicotine are believed, in part, to motivate the excessive cigarette smoking in schizophre-
nia, a disorder associated with deficits in multiple cognitive domains, including low-level
auditory sensory processes and higher-order attention-dependent operations. Objectives:
As N -methyl-d-aspartate receptor (NMDAR) hypofunction has been shown to contribute to
these cognitive impairments, the primary aims of this healthy volunteer study were to: (a) to
shed light on the separate and interactive roles of nAChR and NMDAR systems in the mod-
ulation of auditory sensory memory (and sustained attention), as indexed by the auditory
event-related brain potential – mismatch negativity (MMN), and (b) to examine how these
effects are moderated by a predisposition to auditory hallucinations/delusions (HD). Meth-
ods: In a randomized, double-blind, placebo-controlled design involving a low intravenous
dose of ketamine (0.04 mg/kg) and a 4 mg dose of nicotine gum, MMN, and performance
on a rapid visual information processing (RVIP) task of sustained attention were examined
in 24 healthy controls psychometrically stratified as being lower (L-HD, n=12) or higher (H-
HD) for HD propensity.Results:Ketamine significantly slowed MMN, and reduced MMN in
H-HD, with amplitude attenuation being blocked by the co-administration of nicotine. Nico-
tine significantly enhanced response speed [reaction time (RT)] and accuracy (increased
% hits and d ′ and reduced false alarms) on the RVIP, with improved performance accu-
racy being prevented when nicotine was administered with ketamine. Both % hits and
d ′, as well as RT were poorer in H-HD (vs. L-HD) and while hit rate and d ′ was increased
by nicotine in H-HD, RT was slowed by ketamine in L-HD. Conclusions: Nicotine allevi-
ated ketamine-induced sensory memory impairment and improved attention, particularly
in individuals prone to HD.
Keywords: nicotine, nicotinic acetylcholine receptor, N -methyl-d-aspartate receptor, sensory memory, mismatch
negativity, attention, rapid visual information processing task, schizophrenia
INTRODUCTION
In patients with schizophrenia, the cardinal clinical (positive
and negative) symptoms are, to variable degrees, accompanied
by a wide range of neurocognitive impairments, particularly in
the domains of attention and working memory. The various
cognitive deficits are neither state-related nor specific to sub-
types of the illness, but are considered as enduring features
which remain relatively constant over the course of the disease
and are at the very core of the dysfunction in schizophrenia
patients (Eleväg and Goldberg, 2000; Heinrichs, 2005). As cog-
nitive impairments in schizophrenia are highly correlated with
functional (social and vocational) outcome, and both are relatively
unaffected by dopamine-based antipsychotic drugs, pharma-
cotherapeutic initiatives are focusing on alternative molecular
mechanisms as promising pharmacological targets for improv-
ing cognitive abilities in this disorder (Green, 2007; Tcheremissine
et al., 2012).
Converging evidence from preclinical and human research
points to the therapeutic potential of drugs targeted at nicotinic
acetylcholine receptors (nAChRs) in the treatment of schizophre-
nia cognition (Ochoa and Lasalde-Dominicci, 2007; Evans and
Drobes, 2009; D’Souza and Markou, 2011). nAChRs are strongly
implicated in normal cognitive information processes (Mans-
velder et al., 2006). Nicotine, the primary psychoactive chemical in
tobacco smoke, is a prototypical nAChR agonist and the increased
prevalence of smoking in schizophrenia (∼70–80%) compared
to the general population (∼20%) has been interpreted as a
form of self-medication (Kumari and Postman, 2005; Winterer,
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2010), perhaps to compensate for reduced expression of nAChRs
observed in post-mortem hippocampal and cortical brain regions
of patients (Breese et al., 2000). Although recent evidence of nico-
tine interacting with schizophrenia risk genes with regards to the
expression of endophenotypes such as sensory gating may suggest that
smoking might act as a causal factor for schizophrenia and related
cognitive deficits (Quednow et al., 2012), meta-analysis has shown
significant enhancing effects of acute nicotine on multiple cog-
nitive domains in healthy smokers and non-smokers (Heishman
et al., 2010). Although null findings have been reported in the
cognitive literature, acute doses of nicotine in animal models of
schizophrenia and in non-smoking and smoking schizophrenia
patients also transiently improve elementary pre-attentive sensory
processing deficits as well as performance impairments in higher-
order attention and working memory tasks (Olincy and Stevens,
2007; Radek et al., 2010).
Neurochemical models of schizophrenia have implicated gluta-
matergic mechanisms in general and N -methyl-d-aspartate recep-
tors (NMDARs) in particular. NMDAR-type glutamate receptors
are widely distributed throughout the brain and single sub-
anesthetic doses of NMDAR antagonists, such as phencyclidine or
ketamine, induce transient and reversible neurochemical, symp-
tomatic and neurocognitive aspects of the disorder in healthy
controls, with information processing deficits being observed not
only in higher cortical regions, but also in subcortical systems
and sensory cortices (Javitt, 2010; Adell et al., 2012). Over the
past decade, bottom-up sensory processing deficits have become
increasingly well documented in schizophrenia, co-existing with
top-down, more complex forms of cognitive impairments and
mirroring the pattern of deficits seen with NMDAR antagonists,
thus supporting a NMDAR hypofunction model of the disease
(Kantrowitz and Javitt, 2010).
Disturbance in low-level sensory problems in the auditory sys-
tem is a robust cognitive deficit in schizophrenia patients and is
strongly indexed by impaired generation of an event-related brain
potential (ERP) component – the mismatch negativity (MMN).
Generated within the primary auditory cortex and receiving con-
tributions from frontal cortical generators (Rinne et al., 2000),
the MMN is automatically elicited (at ∼150–200 ms) in an audi-
tory “oddball” paradigm in response to infrequent changes (i.e.,
deviants, such as shifts in sound pitch, intensity, duration, location,
or pattern) in a repetitive stream of auditory stimuli. Presumed to
reflect the stored representations of the characteristics of auditory
stimuli (for seconds to minutes), MMN is an index of auditory sen-
sory (“echoic”) memory, a pre-attentive component of the brain
working memory system (Naatanen et al., 2011). Impaired MMN
generation, which is specific to schizophrenia (vs. other psychiatric
disorders), is well established (Naatanen and Kahkonen, 2009),
with a mean effect size of ∼1 d across studies (Umbricht and Krl-
jes, 2005). Neither typical nor atypical antipsychotics affect the
amplitude or latency of the ERP, and deficits in MMN generation
have been reported in both clozapine- and risperidone-treated
patients (Schall et al., 1998; Umbricht et al., 1998; Umbricht and
Vollenweider, 1999; Kasai et al., 2002).
N -methyl-d-aspartate receptor antagonists have dose-
dependently blocked the MMN response recorded in auditory
primary cortex in animals (Javitt et al., 1994, 1996) and have
diminished the MMN in healthy controls (Umbricht et al., 2000;
Kreitschmann-Andermahr et al., 2001; Heekeren et al., 2008).
Nicotine effects on MMN on the other hand have been rela-
tively consistent with increased amplitude and shorter latencies
to tone pitch deviants being observed in patients with Alzheimer’
disease (Engeland et al., 2002), whereas in healthy controls, nico-
tine has augmented MMN amplitudes to pitch (Harkrider and
Hedrick, 2005), inter-stimulus interval (Martin et al., 2009), and
duration deviants (Baldeweg et al., 2006), with the two former
MMN effects being observed both in smokers and non-smokers,
while the latter effect was shown only in smokers. The latency of
the pitch-MMN has also been shortened with nicotine administra-
tion in non-smokers (Inauri et al., 2005), who have also evidenced
a shortened latency and an increased amplitude of the pitch-MMN
with an acute dose of the selective nAChR agonist AZD3480 (Dun-
bar et al., 2007), as well as an amplitude increase of the visual MMN
with nicotine (Fisher et al., 2010).
In the first of two studies in schizophrenia patients, acute
nicotine treatment did not alter the pitch-MMN amplitude in
non-smoking patients and controls, but in the latter group, it
shortened MMN latency relative both to placebo and to the MMN
latency seen in the patient group (Inami et al., 2007). In the sec-
ond study, conducted in our laboratory, nicotine also increased
duration- (but not pitch) MMN in smoking patients, normal-
izing their amplitude relative to control smokers (Dulude et al.,
2010). These effects were not associated with tobacco withdrawal
symptoms or antipsychotic medication.
Nicotine modulates the release of neurotransmitters other than
acetylcholine (e.g., dopamine, GABA, norepinephrine, and gluta-
mate), with presynaptic nAChRs facilitating NMDAR-mediated
glutamatergic neurotransmission in a multitude of brain regions
including (but not limited to) the prefrontal cortex (Lambe et al.,
2003). nAChRs are heavily expressed in the primary auditory cor-
tex (Soto et al., 2006) where nicotine has enhanced tone-evoked
physiological sensitivity through NMDAR activation (Metherate,
2004). Previous preclinical cognitive studies of nAChR-NMDAR
interactions have shown mixed findings (Timofeeva and Levin,
2011), with some reporting nicotine blockade of the disruptive
pre-attentive (sensorimotor gating), attentional, and mnemonic
effects of NMDAR antagonists (Thompson and Winsaver, 1986;
Terry et al., 2002; Rezvani and Levin, 2003; Spieleway and Markov,
2004; Andreasen et al., 2006; Levin and Rezvani, 2006; Rezvani
et al., 2008), while others reported no interactions, or observed
a potentiation of impairments induced with NMDAR antago-
nist treatment (Levin et al., 2003, 2005; Rezvani and Levin, 2003;
Quarta et al., 2007; Rasmussen et al., 2008). In the few human
studies, the NMDAR antagonist memantine did not oppose the
smoking-induced improvements in sustained attention (Jackson
et al., 2009), and in our work with ketamine, nicotine moderation
of the arousal and attentional modulating actions of this NMDAR
antagonist were found to be dependent on smoker vs. non-smoker
status (Knott et al., 2006, 2011).
Mismatch negativity deficits in schizophrenia are highly corre-
lated with cognitive and functional outcome and as the NMDAR
antagonist model has shown predictive ability for a range of
novel treatments that have reached clinical trials (Large, 2007),
the human ketamine model, together with the use of putative
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endophenotypes such as MMN, offer a good opportunity to study
new drugs with novel and distinct cognitive enhancing mecha-
nisms that go beyond dopamine transmission. In the present study,
the first to investigate the role of NMDAR-mediated glutamater-
gic neurotransmission in nicotine-modulated sensory memory,
the separate and combined actions of nicotine and ketamine were
examined with respect to auditory MMN. In addition, as NMDAR
antagonism also impairs sustained attentional performance, typi-
cally slowing response speed and reducing accuracy in continuous
performance tasks (CPT), a performance pattern similar to that
observed in schizophrenia patients (Newcomer et al., 1999; Krystal
et al., 2005a,b), the study also examined the effects of these drugs
and their interactions on the Rapid Visual Information Process-
ing (RVIP) task, a CPT with putative endophenotypic sensitivity
(Hilti et al., 2010). As it is unclear as to whether ketamine-induced
cognitive impairments reflect the direct effects of ketamine or are
secondary to the induced schizophrenia-like clinical symptoms, we
followed our previous studies and administered a sub-perceptual,
non-psychotomimetic dose of ketamine (Knott et al., 2006, 2011).
Although the human ketamine model in healthy volunteers
is well established and allows for the investigation of neuro-
transmitter systems participating in NMDAR-mediated cognitive
deficiency, these findings may not necessarily be relevant to cogni-
tive impairment in schizophrenia. Confounding factors (prior or
concomitant drug treatment, chronicity, lack of cooperation, lower
education) make the in vivo study of ketamine-drug interactions
in schizophrenia difficult. However, the use of healthy surrogate
populations (e.g., unaffected relatives of patients or people with
schizotypal personality features), defined as groups that feature
a component of the main disease process but do not have the
fully developed condition – is gaining momentum as a potential
methodology for detecting novel drug treatment for schizophrenia
and as such may be relevant for capturing NMDAR-nicotinic inter-
actions regulating cognitive endophenotypes of schizophrenia.
In this approach, schizophrenia is viewed as an extreme of nor-
mally distributed cognitive functions and, for people who express
some of the phenotype without the full disease (psychoses), their
endophenotypes (such as MMN and RVIP) are thought to be more
sensitive to drug effects and/or neurochemical disturbances than
unselected healthy volunteers because they share the same ele-
ments of the disorder (Koychev et al., 2011). One phenotype,
auditory hallucinations (AHs), is strongly associated with psy-
chotic disorders such as schizophrenia but is also observed in
other clinical and non-clinical groups (i.e., are“trans-diagnostic”).
Increasingly, AHs are being investigated in non-psychotic con-
ditions with cognitive and behavioral paradigms developed for
schizophrenia (Waters et al., 2012). As the trait that makes humans
prone to AHs appears to be related to brain areas involved in audi-
tory stimuli processing/speech perception (i.e., auditory cortex;
Kuhn and Gallinat, 2010), the same brain regions participating
in MMN generation, and as schizophrenia patients with AHs (vs.
those without AHs) have exhibited reduced MMN-indexed audi-
tory sensory memory in our laboratory studies (Fisher et al., 2008,
2011, 2012a,b), this present investigation examined the effects of
ketamine, nicotine, and their interactions in healthy volunteers
psychometrically assessed as varying in hallucination/delusion
(HD) proneness.
It was expected that individuals with higher (vs. lower) HD
proneness would exhibit reduced MMN and RVIP performance,
be more susceptible to the detrimental effects of ketamine, and
be more responsive to the enhancing actions of nicotine when
administered alone and in combination with ketamine.
MATERIALS AND METHODS
STUDY PARTICIPANTS
A sample of 24 participants (10 males, 14 females) was selected
from a larger group of 38 healthy volunteers recruited from adver-
tisements in local media and universities. All potential participants
were screened via a semi-structured interview for psychiatric dis-
orders (including alcohol/drug abuse) and general health, and
were also assessed with the Family Instrument for Genetic Studies
(Nurnberger et al., 1994) to rule out those with psychiatric disor-
ders within first-degree relatives. They were also administered the
Bell Object Relations and Reality Testing Inventory (BORRTI; Bell,
1992), a 90-item, self-report true-false pencil-and-paper question-
naire: 45 items assessing object relations, and the other 45 reality
testing, with the latter yielding three subscale factors (Reality of
Distortions, Uncertainty of Perceptions, and Hallucinations and
Delusions), which are thought to identify those with a predispo-
sition for psychotic symptoms. Only the HD subscale was used in
this study. HD scores correlate significantly with the Hallucina-
tory Behavior and Unused Thought Content scales of the widely
used Brief Psychiatric Rating Scale (BPRS; Overall and Gorham,
1962) and HD is the only subscale of the BORRTI on which high
scores are specific to schizophrenia vs. other criterion groups (Bell
et al., 1985). Standardized HD t scores of the total sample ranged
from 30 to 67 (mean= 46.5) and those individuals with the 12
lowest (L-HD) scores (mean= 36.9, range 30–42) and the 12 high-
est (H-HD) scores (mean= 56.3, range 52–67) were selected for
this study. A t score of 60 or more is indicative of a deficit and
three of the H-HD group exhibited scores of 61, 61, and 67. L-HD
and H-HD groups did not differ with respect to their scores on
the Reality of Distortions and Uncertainty of Perception subscale
factors. Groups were similar with respect to age, gender, and non-
smoker/smoker status (L-HD: seven non-smokers, five smokers;
H-HD: six non-smokers, six smokers). All the non-smokers had
not smoked a cigarette in the past year, and the smoking character-
istics of the smoking in the two groups was similar, with smokers
smoking on average for 7.8 years (range 4–12) and smoking a mean
of 16.8 cigarettes/day (range 15–20). None of these participants
reported a personal or first-degree family psychiatric history, use
of medications or a serious medical problem, and none exhibited
abnormal results during a physical examination (with electrocar-
diogram) or with routine laboratory tests (complete blood count,
blood chemistry, urine analysis, and urine toxicology for drug use).
The study was approved by the Research Ethics Board of the
Royal Ottawa Health Care Group and all participants signed an
informed consent prior to study participation.
EXPERIMENTAL DESIGN
The study involved four test sessions couched within a double-
blind, placebo-controlled, cross-over design with two parallel
groups, L-HD and H-HD. Each session involved the intravenous
infusion of ketamine (KI) or a comparable placebo (PI) as well
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as oral administration (gum) of nicotine (NG) or a comparable
placebo (PG). Two of the four test sessions involved a KI and in
the remaining two sessions participants received a PI. Also, in one
of the KI and PI sessions, participants were pretreated with NG,
and in the other two (KI and PI) sessions they were pretreated with
PG. Order of the four treatments (PG–PI, PG–KI, NG–PI, NG–KI)
was counterbalanced and sessions were separated by a minimum
one-day interval.
SESSION PROCEDURES
In each of the four test sessions, participants arrived at the labo-
ratory (08:00 a.m.) following overnight (beginning 12:00 a.m.)
abstinence from food, drugs, alcohol, caffeine, and cigarettes.
Smoking abstinence was verified by an expired air carbon monox-
ide (CO) reading, which was required to be below 5 parts per
million (ppm). Following insertion of an antecubital intravenous
line, a 45-min adaptation period and EEG electrode placement,
participants were administered either NG or PG, and after a 30-
min nicotine absorption period, KI or PI was initiated along with
the RVIP task and simultaneous ERP recordings for MMN. Vital
signs were assessed both before drug treatment and at the end of
the session.
DRUG ADMINISTRATION
Nicotine
An oral dose of nicotine was administered in the form of nicotine
polacrilex gum, providing delivery primarily via buccal absorp-
tion (Hukkanen et al., 2005). A 4 mg Nicorette Plus (Hoechst
Roussell) gum piece or matching placebo was chewed (with nose
plugs, to help reduce any possible sensory impact differences
between nicotine and placebo) over a 25-min period according
to manufacturer guidelines, with participants using an audiotape
to instruct them to bite the gum twice per minute and to park
the gum (i.e., inside the mouth between teeth and cheeks) after
each bite. An additional 5-min absorption period, involving the
chewing of a strong mint gum to help disguise any placebo vs.
nicotine flavor differences, followed the gum chewing so that peak
blood levels from the subsequent infusion of ketamine coincided
with slower rising blood nicotine concentrations, which typically
exhibit a T max of ∼30-min and are expected to range between 10
and 17 ng/ml (Hukkanen et al., 2005). Plasma levels of nicotine
were not assessed. The elimination half-life of plasma nicotine is
approximately 120 min.
Ketamine
Human ketamine studies of acute psychoses typically involve sys-
temic infusions of ketamine at dose levels well below the 1–2 mg/kg
dose range used in human anesthesia, either by administering a
constant dose (0.5 mg/kg) over a ∼60-min period (Krystal et al.,
1994), or by administering an initial bolus (Malhotra et al., 1996)
or loading dose (Newcomer et al., 1999), both followed by infusion
of a maintenance dose of ketamine to achieve steady state ketamine
blood levels over a ∼60-min period. As loading doses of 0.27 and
0.08 mg/kg have produced marked and mild psychotomimetic-like
reactions, respectively, with no subjective effects or measurable
plasma ketamine levels being observed with 0.024 mg/kg (New-
comer et al., 1999), this study utilized an intermediate low loading
dose of 0.04 mg/kg, but no maintenance dose, with the aim of
avoiding the experience of schizophrenia-like clinical symptoms.
Although there are significant relations between MMN Amplitudes
and psychoses-like symptoms induced by ketamine (Umbricht et al.,
2002), our use of a relatively low dose allows us to study the effects
of ketamine independent of psychotic symptoms. An automated
pump apparatus (Imed Gemini PC-1) infused 0.04 mg/kg keta-
mine hydrochloride or placebo [saline (0.9% sodium chloride)
solution] over a 10-min period in order to maximize safety. This
dose level, previously used in our laboratory, had been associated
with arousal EEG, and cognitive changes in healthy volunteers
(Knott et al., 2006, 2011) and produced ketamine blood levels
(25–37 mg/ml) that equated with levels seen in a prior study that
administered a 0.08 mg/kg dose of ketamine (Newcomer et al.,
1999). Although not able to be assessed in all the study participants
due to prohibitive costs, gas chromatography (National Medical
Services, Philadelphia, PA, USA) carried out on five plasma sam-
ples obtained from the PG–KI condition (collected at termination
of the infusion) found KI to produce ketamine levels ranging from
25 to 37 ng/ml (M = 31 ng/ml). These ketamine levels approxi-
mate the average ketamine level reported with the 0.08 mg/kg dose
of ketamine (Newcomer et al., 1999).
STUDY ASSESSMENTS
In order to minimize attention to the auditory stimuli eliciting
the MMN, these ERPs are typically acquired while participants are
engaged in a secondary visual task, which in this case, was the RVIP
task.
RVIP paradigm
Employing the original RVIP paradigm of Wesnes and Warbur-
ton (1984), participants viewed 50-ms duration single digits (1–9)
presented (black on white) in the center of a monitor at a fixed
rate of 110 digits/min, the average inter-stimulus interval being
545 ms and ranging between 445 and 645 ms. Button presses
were required on the detection of targets, which were defined as
the third of three consecutive odd digits. Over the 12-min task,
a total of 1320 digits, including 120 targets (10 per min) were
presented, with each target sequence being separated by a mini-
mum of five digits. Volunteers were instructed to respond (with
right index finger) as quickly and accurately as possible and per-
formance measures included: the number of correct responses
(expressed as % hits), with correct responses being defined as a
button press to the third digit of each target triad within 100–
1000 ms post-stimulus onset; the number (%) of incorrect or false
alarm (FA) responses, defined as button presses to non-target
stimuli, and reaction times (RT) of correct responses. In addi-
tion, signal detection methodology was used to equally weight hits
and FAs into a single measure (d′), which is considered to be a purer
index of perceptual accuracy/sensitivity (Macmillan and Creelman,
1997). Response measures were separated into three successive
time blocks of 4-min each to assess performance changes with
drugs across time.
MMN paradigm
Auditory stimuli eliciting the MMN during ERP recordings con-
sisted of a total of 1200, 80 dB tones (50 ms duration 10 ms
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rise/decay time) presented binaurally through headphones (80 dB
sound pressure level) with a stimulus onset asynchrony of 545 ms
(ranging between 445 and 645 ms) and between individual RVIP
stimuli; resulting in no temporal overlap of the two stimulus
modalities. Ten percent of the tones (deviants) were 100 Hz and
were randomly presented among the standard tones (1000 Hz).
Electrical activity was recorded from frontal (Fz), central (Cz), and
parietal (Pz) midline scalp sites using a linked earlobe reference.
Although choice of reference site may potentially alter outcomes,
ketamine-induced reductions in MMN have been observed with a
variety of references, including linked ears (Gunduz-Bruce et al.,
2012) and linked mastoids (Umbricht et al., 2000). Recordings
were also taken from orbital sites and amplifier bandpass filters
and EEG sampling rate set at 0.1–40 Hz and 250 Hz, respectively.
ERP processing included epoch segmentation (500 ms, beginning
50 ms pre-stimulus onset), ocular correction, artifacting (elim-
inating ocular corrected epochs with EEG> 100µV), baseline
correction, and separate averaging of standard and deviant epochs.
As with the RVIP data, averages were separated into three equal
time blocks, with each block containing 400 stimuli (40 deviants).
There were no significant differences between the study condi-
tions in terms of the number of epochs comprising standard and
deviant averages and all deviant averages contained a minimum
of 30 stimuli. MMNs were derived by digital point-by-point sub-
traction of standard waveforms from deviant waveforms. Since out
own work found frontal MMN in schizophrenia to be effected by acute
nicotine (Dulude et al., 2010) and as ketamine-induced reductions
in MMN in healthy volunteers was evidenced only at frontal (vs.
temporal) sites (Schmidt et al., 2012a), the MMN was measured
from Fz, the site of maximal amplitude. Based on grand averages,
MMN amplitude was defined as the peak negative voltage (relative
to pre-stimulus baseline) in an 80–220 ms window. Latency (ms)
was measured as the time (from stimulus onset) to reach peak
negativity.
STATISTICAL ANALYSIS
Performance measures (hits, FA, d ′, RT) were subjected to sep-
arate split-plot ANOVAs with one between-group factor (HD,
two levels) and three within-group factors (gum, two levels; drug,
two levels; time block, three levels). Similar ANOVAs were car-
ried out with the ERP measures (MMN amplitude and latency).
Greenhouse–Geisser corrections were applied where appropriate
to compensate for violations of sphericity assumed with univariate
ANOVAs. Significant (p< 0.05) main or interaction effects were
followed up with Bonferroni adjusted pairwise comparisons.
Exploration of relationships between MMN and sustained atten-
tion were examined with Pearson r correlations between MMN
amplitude and d′ (collapsed across groups and time blocks) using
placebo data (i.e., PG plus PI condition) as well as change score data,
derived by subtracting values in the placebo condition (PG–PI) from
values derived in each of the three non-placebo sessions.
RESULTS
EFFECTS ON MMN
Robust MMN amplitudes to pitch deviants were shown in each of
the four test sessions and in each of the three time blocks within
each session. No significant main effects were observed for drug,
gum, group, or time block but a significant group× drug× block
(F = 4.05, df= 2, 44, p= 0.031) interaction was demonstrated for
amplitudes. Although exhibiting a general amplitude reduction
with KI, planned comparisons showed that compared to placebo,
KI (vs. PI) significantly reduced MMN only during time block 3
in the H-HD group (p= 0.038). In addition, the MMN amplitude
of the H-HD group during time block 3 was significantly smaller
(p= 0.05) than that of the L-HD group during KI (Figure 1).
Follow-up analysis of a significant group× drug× gum inter-
action (F = 3.945, df= 1, 22, p= 0.049) showed a significant ket-
amine effect in the H-HD group. More specifically, when admin-
istered with PG, KI (vs. PI) significantly (p= 0.004) attenuated
FIGURE 1 | Effects of placebo and ketamine infusion (collapsed across placebo and nicotine gum) on frontal (Fz) mean (±SE) MMN amplitudes of
L-HD and H-HD participants in the three time blocks (B1–B3; *p<0.05).
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FIGURE 2 | Grand averaged waveforms showing MMN changes
(collapsed across time blocks and L-HD and H-HD groups) with
ketamine and placebo infusions when combined with nicotine and
placebo gum (*p<0.05).
FIGURE 3 | Effects of placebo and ketamine infusion (collapsed across
gum conditions, time blocks, and L-HD and H-HD groups) on mean
(±SE) frontal (Fz) MMN latency (*p<0.05).
MMN amplitudes of the H-HD participants (Figure 2). Addition-
ally, in this same condition when KI was combined with PG, the
H-HD exhibited significantly smaller MMN amplitudes than the
L-HD group (p= 0.004). In the H-HD group, KI did not attenuate
MMN when it was administered with NG (i.e., nicotine blocked
KI effects on MMN) and MMN was shown to be significantly
smaller when KI was combined with PG compared to when it was
combined with NG (p= 0.007).
In addition to amplitude, latency of MMN was slightly but sig-
nificantly affected by drug (F = 4.38, df= 1, 22, p= 0.048), with
KI resulting in a slowing of MMN relative to PI (Figure 3).
FIGURE 4 | Effects of placebo and nicotine gum (collapsed across time
blocks, and L-HD and H-HD groups) on mean (±SE)% hits during
placebo (PI) and ketamine (KI) infusion (*p<0.05; ***p<0.001).
EFFECTS ON RVIP
Response accuracy as expressed by % hits varied significantly
in relation to time block (F = 5.27, df= 2, 44, p= 0.01), with
hits being reduced (p= 0.01) in time blocks 2 (M = 79.94%,
SE± 4.98) and 3 (M = 79.16%,SE± 5.18) compared to time block
1 (M = 84.38%, SE± 3.76). A significant gum (F = 11.15, df= 1,
22, p= 0.003) and a gum× drug interaction (F = 10.05, df= 1,
22, p= 0.004) demonstrated a general enhancing effect of NG (vs.
PG) on target detection, which was blocked by KI. Specifically, in
the PI conditions, NG significantly elevated % hits relative to PG
(p= 0.0001) but this gum effect was not observed under KI con-
ditions (Figure 4). The blockade of nicotine-induced increases
in hit rates was further reflected in the comparison of the two
NG conditions, where hits during the combined NG-KI condi-
tion were significantly reduced compared to when nicotine was
combined with PI (p= 0.05) and when KI was administered alone
(p< 0.05).
In a group× gum× block interaction (F = 3.64, df= 1, 44,
p= 0.046), the H-HD group exhibited significantly (p= 0.04)
reduced % hits than the L-HD group in time block 1 (p= 0.05)
and time block 2 (Figure 5). For the H-HD group, NG (relative to
PG) was shown to elevate hit rate in the H-HD during time block
1 (p= 0.006) and during time block 2 (p= 0.001).
As shown in Figure 6, FAs were moderated by a gum× time
block interaction (F = 3.23, df= 2, 44, p= 0.032), with NG act-
ing to prevent the response errors seen in time block with PG
(p= 0.038).
The analysis of d ′ yielded a significant gum (F = 13.63, df= 1,
44, (p= 0.001), drug× gum (F = 7.06, df= 1, 44, (p= 0.014)
and a drug× gum× block× group effects (F = 3.64, df= 1, 44,
(p= 0.05). NG (vs. PG) increased scores (p= 0.001) but this was
shown only during PI (not KI) and, as displayed in Table 1, was
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FIGURE 5 | Effects of placebo and nicotine gum (collapsed across placebo and ketamine infusions) on mean (±SE) % hits of L-HD and H-HD groups in
the three times blocks (B1–B3). (*p<0.006; **p<0.001; t, p<0.05 comparing L-HD and H-HD with placebo gum in B1 and B2).
FIGURE 6 | Effects of placebo and nicotine gum (collapsed across
placebo and ketamine infusions, and L-HD and H-HD groups) on mean
(±SE) % false alarms in the three time blocks (B1–B3; *p<0.05).
limited to the H-HD group during time block 1 (p= 0.001) and 2
(p= 0.009). During administration of placebo (PG–PI), d ′ scores
of the H-HD group were also significantly lower than those of
the L-HD group in time block 1 (p= 0.05) and 3 (p= 0.05). Also
for the H-HD group in the combined Ki-NG condition, d ′ scores
significantly declined from block 1 to block 2 (p= 0.01).
Response speed was significantly influenced by gum (F = 4.77,
df= 1, 22, p= 0.040), with NG speeding RT relative to PG. In a
group× drug interaction (F = 4.77, df= 1.22, p= 0.040) RT of
the H-HD group was found to be significantly slower (p= 0.032)
than the L-HD during administration of PG and PI (Figure 7).
Although not affecting the H-HD participants, there was a trend
for KI (vs. PI) to slow RT (p= 0.06) in the L-HD group, and during
the KI condition there were no differences in RT between the L-HD
and H-HD groups.
CORRELATIONS
No significant correlations were observed between MMN and d′ in
the placebo condition (PG–PI) nor were there any significant cor-
relations between ketamine/nicotine-induced changes in MMN and
ketamine/nicotine-induced change in d′.
DISCUSSION
To our knowledge, this is the first study to investigate the moderat-
ing role of nicotine on ketamine-induced changes in both sensory
and attentional processing, two domains which are highly dysfunc-
tional in schizophrenia and are differentially modulated by the
NMDAR antagonist ketamine and the nAChR agonist nicotine.
Specifically, the study investigated the hypothesis that MMN – an
index of auditory sensory memory that depends on intact NMDAR
functioning, would be impaired by ketamine but not when co-
administered with nicotine. The results support this hypothesis
in that healthy volunteers, assessed to be more prone to experi-
encing hallucinatory activity (H-HD), evidenced a significantly
diminished MMN generation with ketamine alone but not when
ketamine was combined with nicotine. During ketamine infu-
sion, MMN amplitudes of H-HD participants were significantly
reduced compared to L-HD participants, assessed to be less prone
to HD.
Although not observed in one previous study (Oranje et al.,
2000), the reduction of MMN with intravenous ketamine is consis-
tent with prior reports of MMN attenuation in healthy volunteers
with sub-anesthetic doses of the NMDA antagonist ketamine
(Umbricht et al., 2000) and parallels the reduction of MMN in
monkeys following infusion of NMDAR antagonists into pri-
mary auditory cortex (Javitt et al., 1992, 1994, 1996) as well as
the dose-dependent blockade of the MMN recorded from rat
auditory cortex after intra-peritoneal injections of the NMDAR
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Table 1 | Mean/±SE d ′ scores of L-HD and H-HD groups across treatment conditions and time blocks (B1–B3).
Treatment L-HD H-HD
B1 B2 B3 B1 B2 B3
PG–PI 3.49/0.18 3.45/0.27 3.39/0.28 3.10/0.18 3.02/0.27 2.95/0.28
PG–KI 3.44/0.23 3.38/0.24 3.04/0.29 3.26/0.23 3.04/0.24 3.38/0.29
NG–PI 3.66/0.19 3.62/0.24 3.49/0.25 3.86/0.19 3.27/0.24 3.44/0.25
NG–KI 3.46/0.21 3.23/0.2 3.44/0.25 3.26/0.21 3.29/0.22 3.05/0.25
FIGURE 7 | Effects of placebo and nicotine gum (collapsed across
placebo and ketamine infusions and the three time blocks) on mean
(±SE) reaction time (RT) in L-HD and H-HD groups (*p<0.05).
antagonist, MK-P01, and memantine (Tikhonravov et al., 2008,
2010). Together with the observation of robust reductions of
MMN (effect size of 0.99) in schizophrenia patients (Umbricht
and Krljes, 2005) and the wealth of evidence suggesting that psy-
chosis is secondary to NMDAR hypofunction with a downstream
effect in dopaminergic activity (Fu et al., 2000; Lin et al., 2012),
these present findings provide indirect evidence supporting the
glutamate/NMDAR hypothesis of schizophrenia and specifically
reinforce the implication that deficits in glutamatergic signaling
underlie auditory sensory memory impairment characterizing this
disorder.
Unlike previous cognitive and MMN studies that purposefully
used ketamine doses which were psychotomimetic (i.e., typically
involving initial loading dose of ∼0.25 mg/kg followed by a main-
tenance dose of ∼0.5–0.9 mg/kg/h) and transiently reproduced
schizophrenia-like negative and positive symptoms in healthy vol-
unteers (e.g., Newcomer et al., 1999), this present study used a
single, low dose bolus infusion (0.04 mg/kg) which had previously
been shown to induce only mild subjective arousal and euphoric
but not clinically relevant behavioral changes. MMN is indirectly
proportional to the prevalence of negative symptoms (Urban
et al., 2007) and as such, ketamine-induced behavioral effects
with psychotomimetic doses may potentially contribute to cogni-
tive deficits including sensory processing abnormality. However,
in healthy controls administered the psychotomimetic psilocybin
(a 5-HT2A agonist), a reduction in MMN was not shown despite
the experienced marked behavioral changes (Umbricht and Vol-
lenweider, 1999). Viewed in the context of previous reports of
greater MMN deficits in patients prone to AH (Fisher et al., 2008,
2011, 2012a,b) and of studies showing the magnitude of MMN
deficit in patients to be correlated with clinical ratings of halluci-
natory behavior (Youn et al., 2003; see also, Hirayasu et al., 1998
and Thonnesen et al., 2008), our finding of diminished MMN
generation with a low sub-psychotomimetic dose of ketamine in
H-HD (vs. L-HD) participants suggests that glutamatergic neu-
rotransmission in the auditory cortex of individuals with a trait
that predisposes to AH may be more vulnerable to disruption of
NDMAR activity.
Keeping in mind that AHs of non-patients may not be similar
to those of psychotic or non-psychotic clinical patients (Daalman
et al., 2011), hallucinations in general are essentially perceptions
that arise through an interaction stemming from neural activa-
tions and top-down activity. The basic neural signal contributing
to a tonic trait-like vulnerability to experience AHs appears to
arise from hyperactivation of functional networks involving the
auditory cortex that generate aberrant auditory signals (Kuhn
and Gallinat, 2010; Waters et al., 2012). Although AHs were not
formally assessed during the testing sessions, it is possible that
NMDAR antagonism induced an abnormality in auditory signal-
ing and increased hallucinating activity, which may have impacted
MMN generation. In support of this argument, patients in gen-
eral exhibit reduced sensory-level processing of auditory input
(e.g., diminished auditory acuity, elevated thresholds for tone dis-
crimination; Mathew et al., 1993; Holcomb et al., 1995; Strous
et al., 1995; Wexler et al., 1998; Rabinowicz et al., 2000); patients
with (vs. without) AHs have greater difficulty in sound (speech)
discrimination (Hugdahl et al., 2008), and the temporal cortex
evidences both high glutamate levels in patients (Marsman et al.,
2011) and hypofunctional activation in controls during ketamine
infusion (Hugdahl et al., 2008). However, impaired auditory MMN
generation during ketamine infusion is unlikely to be related to
competing influences resulting from increasing auditory verbal
hallucinations as organized AH (i.e., identifiable as speech) as
seen in established schizophrenia are rarely observed during a ket-
amine challenge (Kantrowitz and Javitt, 2010). Also, any evoked
auditory disturbances during ketamine infusion resemble the pat-
tern observed in the early course of schizophrenia and as such,
altered auditory processing during a ketamine challenge may be
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viewed more as a model of prodromal or acute incipient schizo-
phrenia, rather than late, chronic schizophrenia (Kantrowitz and
Javitt, 2010).
Nicotine alone did not affect MMN but it prevented the MMN
attenuation induced with ketamine. Failure to observe enhanced
sensory memory processing with nicotine as shown in earlier
reports may be related to methodological differences between
studies, including dose and route of nicotine administration, stim-
ulus feature and presentation parameters, ERP recording and
processing procedures, and composition of participant samples.
However, the ability of nicotine to block the NMDAR antagonist
actions of ketamine on auditory sensory memory is consistent
with findings that acetylcholine is one of the major modulators
of auditory cortical activity (Edeline, 2003; Soto et al., 2006), with
both high (α4β2) and low (α7) nicotine affinity nAChRs being
densely, and widely expressed in the auditory pathway (Morley and
Happe, 2000), particularly where thalamocortical inputs terminate
(Metherate, 2004; Bieszczad et al., 2012).
The underlying mechanism of nicotine’s protective action
is unclear and although it may involve the regulation of sen-
sory processes by tonic release of endogenous acetylcholine at
nAChRs, thalamocortical synapses are excitatory and glutamater-
gic (Kharazia and Weinberg, 1994). Hence, nicotine blockade
of ketamine effects may implicate nicotinic regulation of thal-
amocortical glutamate release by presynaptic (or preterminal)
nAChRs, and possibly nicotinic regulation of GABAergic interneu-
rons (Radcliffe et al., 1999; Schilström et al., 2000; Metherate and
Hsieh, 2003; Liang et al., 2008; Intskirveli and Metherate, 2012).
As an additional or alternative mechanism, nicotinic agonists have
also been shown to inhibit NMDAR-mediated cortical currents,
possibly by displacing the obligatory NMDAR co-agonist glycine
(Flores-Hernandez et al., 2009). Regardless of the mechanism
of action, these present study findings of diminished ketamine-
induced MMN impairment were observed with a smoking-dose
of nicotine, as was the previous finding of nicotine-induced nor-
malization of MMN in schizophrenia patients (Dulude et al.,
2010). Together they provide tentative support for the contention
that excessive tobacco use in schizophrenia in patients may be an
attempt to correct sensory deficiencies related to dysfunctional
nAChR and/or NMDAR systems. The increase in MMN latency
with NMDAR antagonism, reported previously by other studies
using larger ketamine doses (Umbricht et al., 2000; Kreitschmann-
Andermahr et al., 2001; Roser et al., 2011), was not moderated by
nicotine, suggesting that nicotine’s protective actions in the human
ketamine model are specific to the strength and not the speed of
sensory memory processes.
Performance in the RVIP task was also investigated and was
generally found to be enhanced during acute nicotine administra-
tion, with both response accuracy (hit rate and d′) and speed (RT)
being improved relative to placebo. Indexing sustained attention
and working memory aspects of cognition, task performance in
CPT paradigms such as RVIP has consistently been impaired both
in schizophrenia (Hilti et al., 2010; Barch et al., 2012) and tobacco
abstaining smokers (Heishman, 1999). Nicotine has been shown
to improve CPT efficiency in schizophrenia (Smith et al., 2006;
Barr et al., 2008), with attentional improvements in some stud-
ies being reported to be selective for non-smoking (vs. smoking)
patients (Harris et al., 2004). For sustained attention measured with
RVIP, nicotine improved but did not normalize performance in schiz-
ophrenia and it exerted no significant reversal of the impaired frontal-
parietal-cingulate-thalamic attention network associated with schiz-
ophrenia (Hong et al., 2011). Although typically viewed as a task of
sustained attention, RVIP also involves a significant working mem-
ory component and nicotine improvement of RVIP and attention-
dependent tasks may be related to its demonstrated ability to
activate posterior (parietal) brain areas traditionally associated
with visual attention (Lawrence et al., 2002) and/or to increase
functional connectivity in frontal, executive-based cortical regions
(Jacobsen et al., 2004).
The increased hit rate and d ′ seen with nicotine (vs. placebo)
gum during placebo infusion was absent when nicotine was
administered with ketamine. Ionotropic- but not metabotropic-
glutamate antagonist treatment also blocked nicotine improved
response accuracy in rodent attentional tasks (Quarta et al., 2007;
Amitai and Markou, 2009). Together these observations suggest
that nAChR modulation of glutamate release underlies nicotine-
enhanced target detection and is diminished by NMDAR blockade.
However, nAChR and NMDAR ligands appear to overlap in their
ligand affinities (Aracava et al., 2005; Plazas et al., 2007) and as
anesthetics are potent inhibitors of presynaptic nAChRs, with
ketamine being shown to block α4 β2 nAChRs (Irnaten et al.,
2002; Tassonyi et al., 2002), it may have attenuated the nicotinic
stimulation required for improvements in correct response rates.
Nicotine-facilitated target detection was found to vary between
HD groups, with increased d ′ and hit rates during nicotine (vs.
placebo) administration being limited to the higher scoring indi-
viduals (H-HD), who also exhibited reduced hit rates and d ′ com-
pared to L-HD participants in the non-drug condition. Although
in schizophrenia hallucinators, the reduced activation shown in
primary auditory cortex during auditory target detection was not
seen in visual cortex (Ford et al., 2009), recent neurophysiological
evidence has pointed to early visual processing deficits in patients
who tend to hallucinate (Kayser et al., 2012). Perhaps extending
to healthy controls with a hallucinating propensity, these find-
ings in patient hallucinators suggested a broader early perceptual
deficit that extends beyond the auditory modality. The perfor-
mance improving effect of nicotine on RVIP in H-HD is consistent
with previous ERP research showing preferential enhancement
in visual (vs. auditory) processing (e.g., increased amplitude of
the N100 and P300 ERPs) with smoking/nicotine (Knott, 1989;
Knott et al., 1995, 1999; Pritchard et al., 2004) and it also par-
allels reports showing nicotine – induced cognitive facilitation
to be more prevalent in poorer performing, cognitively deficient
populations (Newhouse et al., 2004).
The H-HD group were also slower in responding to RVIP tar-
gets than the L-HD group but ketamine, not nicotine, influenced
response speed only in the L-HD participants, increasing RT rel-
ative to placebo. Together with reduced target detection rates,
response slowing in non-patient hallucinators support and extend
the contention applied to schizophrenia voice-hearers (Ford et al.,
2009), that their auditory cortex may be “turned on” and tonically
“tuned in”to internal acoustic information at the cost of processing
not only external sounds but on the basis of these findings, exter-
nal visual input as well. Perhaps reflecting a “floor” effect that
prevents further slowing of RT, ketamine-induced slowing was
not seen in H-HD and its appearance in L-HD indicates that,
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as shown with nicotine’s attentional enhancing properties, the
RVIP impairing actions of NMDAR blockade in healthy volun-
teers are baseline dependent. MMN failed to show any relationship
to d′ in the placebo or active conditions. In schizophrenia, MMN
has been found to be related and contribute to higher-order cogni-
tive impairments as well as deficits in social cognition (Javitt et al.,
1995; Baldeweg et al., 2004; Sehatpour et al., 2010; Wynn et al.,
2010). Unlike our present findings, modeling study suggested keta-
mine reductions in MMN in healthy volunteers to be mediated by
changes in short-term plasticity (of “forward” inter-regional connec-
tions) of the auditory hierarchy, which significantly correlated with
ratings of ketamine-induced impairments in cognition and control
(Schmidt et al., 2012b). Although RVIP may be an exception, re-
examination of this task in larger sample of healthy volunteers and
patients and with larger doses of nicotine and ketamine may show
unique relationships between MMN and sustained attention that are
moderated by SZ pathology and/or nicotinic/glutamatergic activity.
LIMITATIONS
Methodological weakness in the present study may have moder-
ated the findings and limited the conclusions and implications of
this research. First, both nicotine and ketamine were administered
as single doses and accordingly, it is not know if the observed
results with each drug and their combination are dose-dependent.
Second, ketamine was infused as a low bolus dose and the related
cognitive findings may be distinct from those observed with the
majority of human ketamine studies that have assessed cognition
with sustained psychotogenic doses of this drug. Also, blood lev-
els of the two drugs were not assayed to determine bioavailability
and the cognitive effects of nicotine administered via slow buccal
absorption may not mirror the effects of acute smoking, which
delivers rapid nicotine boli to the brain. Performance assessments
were also limited and did not encompass the range of information
processing deficits that characterize schizophrenia, each of which
are valid targets for novel nicotinic and glutamatergic therapies.
Finally, the L-HD and H-HD study samples were relatively small
and were drawn from a healthy population and although there are
advantages to this approach, similar challenge studies are required
with healthy surrogate populations (e.g., schizotypal personality
disorder, unaffected first-degree relatives of patients) with genetic
links to schizophrenia.
CONCLUSION
This study produced novel findings which underscore the potential
role of nAChR and NMDAR systems and their interplay in the eti-
ology of core neurocognitive deficits characterizing schizophrenia.
The disturbance in sensory and attentional processing evident with
a sub-psychotomimetic dose of ketamine reflects the widespread
distribution of brain NMDARs and their sensitivity to minimal
perturbations in glutamate signaling. Nicotine exhibited strong
attentional enhancing properties, which in part were dependent on
glutamate neurotransmission and were also evident by its ability to
counter impaired deviance detection induced with NMDAR block-
ade. That these effects were moderated by a hallucinatory trait in
a healthy population suggests that nicotine’s sensory-attentional
properties and its modulatory effects on NMDAR systems are
relevant to neurocognitive deficits in schizophrenia and may be
specific to patient subtypes.
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